摘要
目的:评价齐拉西酮治疗躁狂症临床对照研究的疗效差异。方法:应用循证医学方法对符合标准的6项研究进行分析,评价齐拉西酮在心境稳定剂的基础上,空白对照以及阳性药物对照治疗躁狂症在治疗过程中症状学差异和有效率、痊愈率的差异。结果:1.在心境稳定剂的基础上,齐拉西酮组比空白对照组症状改善显著,差异有统计学意义,P<0.01;有效率显著高于对照组,差异有统计学意义,P<0.01,痊愈率也同样高于对照组。差异有统计学意义,P<0.01。2.在心境稳定剂的基础上,齐拉西酮组比阳性药物对照组症状改善逊色,差异有统计学意义,P<0.01,但95%可信区间为OR=0.86(0.55-1.17)。有效率和痊愈率均高于对照组,但均没有统计学意义,P>0.05。结论:齐拉西酮联合治疗躁狂症有良好的效果,与阳性药物对照比较相似。
Objective： To assess the difference in ziprasidone treatment of mania controlled in clinical. Methods： 6 studies meeting our criteria were analyzed by based-evidence medicine, comparing their difference in efficacy. Results： 1. Comparing to the blank group, ziprasidone group had higher changing on symptoms, effective rate （P 〈 0. 01 ）. 2. Comparing to the positive drugs, ziprasidone group had lower changing on of symptoms（P 〈0. 01 ）. The OR was 0. 86（0. 55-1.17）. Conclusion： Ziprasidone is a better drugs in the treatment of patients with mania, its effects similar to the other positive drugs.
出处
《中国药物评价》
2012年第4期288-292,共5页
Chinese Journal of Drug Evaluation
